Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: The FRALLE 93 study

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1496-1503

  Oudot, Caroline ^b   Auclerc, Marie Françoise ^b   Levy, Vincent ^b   Porcher, Raphaël ^b   Piguet, Christophe ^b   Perel, Yves ^b   Gandemer, Virginie ^b   Debre, Marianne ^b   Vermylen, Christiane ^b   Pautard, Brigitte ^b   Berger, Claire ^b   Schmitt, Claudine ^b   Leblanc, Thierry ^b   Cayuela, Jean Michel ^b   Socie, Gérard ^b   Michel, Gérard ^b   Leverger, Guy ^b   Baruchel, André ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ADULT; ANALYSIS OF VARIANCE; CHILD; COMPARATIVE STUDY; FRANCE; INFANT; LYMPHATIC LEUKEMIA; PROSPECTIVE STUDY; REMISSION; RISK FACTOR; STATISTICAL MODEL; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HUMANS; INFANT; LOGISTIC MODELS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 41149102414     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2820     Document Type: Article

References (75)

1. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004
2. Gaynon PS, Trigg ME, Heerema NA, et al: Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14:2223-2233, 2000
3. Gustafsson G, Schmiegelow K, Forestier E, et al: Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation - Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14:2267-2275, 2000
4. Harms DO, Janka-Schaub GE: Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 14:2234-2239, 2000
5. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90 - German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000
6. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001
7. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994
8. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL - BFM 86. Blood 84:3122-3133, 1994
9. Silverman L, Gelber R, Young M, et al: Induction failure in acute lymphoblastic leukemia of childhood. Cancer 85:1395-1404, 1999
10. Felice MS, Zubizarreta PA, Alfaro EM, et al: Childhood acute lymphoblastic leukemia: Prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol 23:411-415, 2001
11. Lilleyman JS, Eden OB: UKALL trials I-VIII: Clinical features and results of treatment in four groups of children with adverse prognostic features. Med Pediatr Oncol 14:182-186, 1986
12. Gajjar A, Ribeiro R, Hancock M, et al: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292-1295, 1995
13. Griffin TC, Shuster JJ, Buchanan GR, et al: Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Leukemia 14:792-795, 2000
14. Ribera JM, Ortega JJ, Oriol A, et al: Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 87:154-165, 2002
15. Goldberg J, Silverman L, Levy D, et al: Childhood T-cell acute lymphoblastic leukemia: The DFCI ALL consortium. J Clin Oncol 21:3616-3622, 2003
16. Schrappe M: Evolution of BFM trials for childhood ALL. Ann Hematol 83:S121-S123, 2004 (suppl 1)
17. Pieters R, Schrappe M, De Lorenzo P, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 370:240-250, 2007
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, John Wiley, 1989, pp 140-145
20. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, NY, Chapman and Hall, 1993
21. Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
22. Pui CH, Simone JV, Hancock ML, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St Jude total therapy study X. Leukemia 6:150-157, 1992
23. Tubergen D, Gilchrist G, O'Brien R, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Children'S Cancer Group phase III trial. J Clin Oncol 11:527-537, 1993
24. Schorin MA, Blattner S, Gelber R, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740-747, 1994
25. Chessells JM: Intensification of treatment and survival in ALL children. Lancet 348:143-148, 1995
26. Veerman AJ, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
27. Nachman J, Sather HN, Gaynon PS, et al: Augmented BFM therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukaemia and unfavorable presenting features: A report from the Children's Cancer Group. J Clin Oncol 15:2222-2230, 1997
28. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
29. Kamps WA, Bokkerink JP, Hahlen K, et al: Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 94:1226-1236, 1999
30. Reaman GH, Sposto R, Sensel MG, et al: Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 17:445-455, 1999
31. Wheeler KA, Richards SM, Bailey CC, et al: Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: Results from Medical Research Council UKALL X and XI. Blood 96:2412-2418, 2000
32. Arico M, Valsecchi MG, Conter V, et al: Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 100:420-426, 2002
33. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al: BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 16:1099-1111, 2002
34. Pui CH, Sandlund JT, Pei D, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104:2690-2696, 2004
35. Arico M, Conter V, Valsecchi MG, et al: Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia: The AIEOP ALL-9501 study. Haematologica 90:1186-1191, 2005
36. Early A, Preisler HD, Gottlieb A: Treatment of refractory adult acute lymphocytic leukaemia and acute undifferentiated leukaemia with anthracycline antibiotic and cytosine arabinoside. Br J Haematol 48:369-375, 1981
37. Schaison G, Olive D, Leverger G, et al: Treatment of acute lymphoblastic leukemia: Protocol Fralle 83-87. Haematol Blood Transfus 33:467-472, 1990
38. Chessells JM, Bailey CC, Richards S: MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. Leukemia 2:S157-S161, 1992 (suppl 2)
39. Ochs J, Rivera GK, Pollock B, et al: Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. Cancer 66:1671-1677, 1990
40. Mehta J, Powles R, Horton C, et al: Bone marrow transplantation for primary refractory acute leukemia. Bone Marrow Transplant 14:415-418, 1994
41. Conter V, Arico M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with BFM-based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995
42. Steinherz P, Gaynon P, Breneman J, et al: Treatment of patients with acute lymphoblastic leukemia with bulky extra-medullary disease and T-cell phenotype or other poor prognostic features. Cancer 82:600-612, 1998
43. Attarbaschi A, Mann G, Dworzak M, et al: Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: Significance and therapy response. Med Pediatr Oncol 39:558-565, 2002
44. Crist W, Carroll A, Shuster J, et al: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome - A Pediatric Oncology Group study. Blood 76:489-494, 1990
45. Schrappe M, Arico M, Harbott J, et al: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730-2741, 1998
46. Arico M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
47. Champagne M, Capdeville R, Krailo M, et al: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 104:2655-2660, 2004
48. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104:3507-3512, 2004
49. Delannoy A, Delabesse E, Lheritier V, et al: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: A result of the GRAAL AFR09 study. Leukemia 20:1526-1532, 2006
50. De Labarthe A, Rousselot P, Huguet-Rigal F, et al: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 109:1408-1413, 2007
51. Gaynon PS, Desai AA, Bostrom BC, et al: Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer 80:1717-1726, 1997
52. Sandlund JT, Harrison PL, Rivera G, et al: Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 100:43-47, 2002
53. Miller DR, Coccia PF, Bleyer WA, et al: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Children's Cancer Study Group. J Clin Oncol 7:1807-1815, 1989
54. Donadieu J, Auclerc MF, Baruchel A, et al: Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables-French Acute Lymphoblastic Leukaemia study group. Br J Haematol 102:729-739, 1998
55. Chessells JM, Richards SM, Bailey CC, et al: Gender and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL trials. Br J Haematol 89:364-372, 1995
56. Shuster JJ, Wacker P, Pullen J, et al: Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 16:2854-2863, 1998
57. Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukemia: Current status and future perspectives. Lancet Oncol 2:597-6007, 2001
58. Ishii E, Eguchi H, Matsuzaki A, et al: Outcome of acute lymphoblastic leukemia in children with AL regimen: Impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol 37:10-19, 2001
59. Crist W, Pullen J, Boyett J, et al: Clinical and biologic features predict a poor prognosis in acute lymphoblastic leukemia in infants: A Pediatric Oncology Group study. Blood 67:135-140, 1986
60. Sather H: Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14:166-172, 1986
61. Chessells JM, Hall E, Prentice HG, et al: The impact of age on outcome in lymphoblastic leukaemia: MRC UKALL X and XA compared - A report from the MRC Paediatric and Adult Working Parties. Leukemia 12:463-473, 1998
62. Lilleyman JS, Hann IM, Stevens RF, et al: French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance. J Clin Pathol 39:998-1002, 1986
63. Rivera G, Dahl GV, Bowman WP, et al: VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures. Cancer 46:1727-1730, 1980
64. Giona F, Testi AM, Annino L, et al: Treatment of primary refractory and relapsed acute lymphoblastic leukemia in children and adults: The GIMENA/AIEOP experience. Br J Haematol 86:55-61, 1994
65. Balduzzi A, Valsecchi MG, Uderzo C, et al: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 366:635-642, 2005
66. Cavé H, van der Werff ten Bosch J, Suciu S, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 339:591-598, 1998
67. Coustan-Smith E, Behm FG, Sanchez J, et al: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351:550-554, 1998
68. Neale GA, Coustan-Smith E, Stow P, et al: Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 18:934-938, 2004
69. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352:1731-1738, 1998
70. Coustan-Smith E, Sancho J, Hancock ML, et al: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691-2696, 2000
71. Coustan-Smith E, Sancho J, Behm FG, et al: Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100:52-58, 2002
72. Pui CH, Campana D: New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14:783-785, 2000
73. Chiaretti S, Li X, Gentleman R, et al: Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103:2771-2778, 2004
74. Holleman A, Cheok MH, den Boer ML, et al: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004
75. Winter SS, Jiang Z, Khawaja HM, et al: Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 110:1429-1438, 2007